Status:
WITHDRAWN
SP Resistance and Falciparum Malaria Transmission
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Plasmodium Falciparum Malaria
Eligibility:
All Genders
5-99 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to study resistance to current malaria treatments and affordable alternatives for uncomplicated malaria. Resistance occurs in areas where these treatments are used frequen...
Detailed Description
Drug-resistant Plasmodium falciparum is a major threat to global public health and new strategies are needed to deter spread of resistance to available and forthcoming antimalarial drugs. This study s...
Eligibility Criteria
Inclusion
- Age more than 5 years Positive blood smear for falciparum malaria Informed consent from participant or parent Intention to remain in the study area for at least 4 weeks from the time of enrollment
Exclusion
- Mixed Plasmodium infection Parasitemia \> 10% Hematocrit \< 15% Respiratory distress Spontaneous bleeding (from gums, nose, gastrointestinal tract, etc.) Recent seizures or coma Prostration or weakness, so that the patient cannot sit or walk, with no obvious neurological explanation Inability to drink Persistent vomiting History of allergy or adverse reaction to sulfadoxine-pyrimethamine (SP) or sulfa drugs Known pregnancy
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00299247
End Date
December 1 2006
Last Update
January 30 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Malaria Vaccine and Drug Development Center
Cali, Colombia
2
Universidad del Valle Sede San Fernando
Cali, Colombia